US Patent

US9908845 — Aryl ethers and uses thereof

Method of Use · Assigned to Peloton Therapeutics Inc · Expires 2034-09-05 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of using HIF-2Î± inhibitors, such as certain aryl ethers, for treating cancer.

USPTO Abstract

The present disclosure relates to HIF-2Î± inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2Î± scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Drugs covered by this patent

Welireg (BELZUTIFAN) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4195`	—	Welireg

Patent Metadata

Patent number: US9908845
Jurisdiction: US
Classification: Method of Use
Expires: 2034-09-05
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Peloton Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.